| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
DuPont Pharmaceuticals Company, StineHaskell Research Center, Haskell-1, P.O. Box 30, Newark, DE (BDC); and University of Pennsylvania, University Laboratory Animal Resources, Philadelphia, PA (VME)
The study of mutant mice with altered or deficient hematopoietic or hemostatic gene products provides a challenge to the researcher, particularly when genetic alterations lead to lethal phenotypes. The following review provides a framework for understanding murine hematopoiesis, based on work with mutant mice, and details experimental approaches used to evaluate these animals. Mice with deficiencies in hemostatic and fibrinolytic system proteins are discussed, and the investigation of their phenotypes is reviewed.
Key words: Coagulation; fibrinolysis; hematology; hematopoiesis; hemostasis; knockout; mice.
Request reprints from Dr. Bruce D. Car, DuPont Pharmaceuticals Company, StineHaskell Research Center, Haskell-1, P.O. Box 30, Newark, DE 19714-0030 (USA). E-mail: bruce.d.car{at}dupontpharma.com.
This article has been cited by other articles:
![]() |
L. Han, M. Dias Figueiredo, K. A. Berghorn, T. N. Iwata, P. A. Clark-Campbell, I. C. Welsh, W. Wang, T. P. O'Brien, D. M. Lin, and M. S. Roberson Analysis of the Gene Regulatory Program Induced by the Homeobox Transcription Factor Distal-less 3 in Mouse Placenta Endocrinology, March 1, 2007; 148(3): 1246 - 1254. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Brayton, M. Justice, and C. A. Montgomery Evaluating Mutant Mice: Anatomic Pathology Vet. Pathol., January 1, 2001; 38(1): 1 - 19. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |